Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Receives NCI Grant to Develop siRNA-Based Lung Cancer Rx

Premium

Sirnaomics this week announced that it has received a Small Business Innovation Research grant from the National Cancer Institute to develop novel siRNA-based therapeutics for lung cancer.

According to the NIH, the six-month grant began on June 1 and is worth $250,000. The company will use the funds to develop multi-targeted siRNA drugs for non-small cell lung cancer.

"We will test this drug candidate in A549 and H460 xenograft tumor models for its antitumor efficacy and safety profiles," the company said in the grant's abstract. "We will also use HKP and PTL nanoparticle[s] to further enhance the siRNA cocktail therapeutics, targeting EGFR, VEGF, Cox-2, or PDGF oncogenic genes."

Sirnaomics added that it will also examine the efficacy of its therapies in combination with existing small-molecule and antibody drugs in animal models.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.